The global bladder cancer drugs market is expected to grow from $1.98 billion in 2021 to $2.35 billion in 2022 at a compound annual growth rate (CAGR) of 19.1%. The market is expected to reach $4.45 billion in 2026 at a CAGR of 17.3%.
North America is the largest region in the bladder cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The American Cancer Society’s estimates for bladder cancer in the United States for 2021 are about 83,730 new cases of bladder cancer. In addition, the rising geriatric population, unhygienic sedentary lifestyle, and smoking habits are increasing the prevalence of most cancer cases.
When the cells that make up the urinary bladder begin to proliferate out of control, bladder cancer develops. More cancer cells can form a tumor and spread to other places of the body as time goes on. The bladder wall is made up of multiple layers. Each layer is made up of many cell types. The urothelium or transitional epithelium, which lines the inside of the bladder, is where most bladder malignancies begin. Cancer progresses to a higher stage, gets more advanced, and is more difficult to cure when it spreads into or through the other layers of the bladder wall. Cancer may spread outside the bladder and into neighboring structures over time. It could spread to nearby lymph nodes or other organs.
Bladder Cancer Drugs Market size & Market analysis
The most frequent type of bladder cancer is urothelial carcinoma, also known as transitional cell carcinoma (TCC). Urothelial carcinoma is virtually always been the cause of bladder cancer. Squamous cell carcinomas account for about 1% to 2% of bladder malignancies in the United States. The cells, when viewed under a microscope, resemble the flat cells present on the skin’s surface. Squamous cell carcinomas of the bladder are almost always invasive. Adenocarcinomas make up roughly 1% of all bladder cancers. These cancer cells have a lot in common with colon cancer gland-forming cells. Almost of bladder adenocarcinomas are invasive. Small-cell carcinomas account for less than 1% of bladder cancers. They begin in neuroendocrine cells, which are nerve-like cells. These cancers grow quickly and require chemotherapy, similar to that used to treat small cell carcinoma of the lung. Sarcomas begin in the bladder’s muscle cells, but they are extremely rare. Soft Tissue Sarcoma and Rhabdomyosarcoma have more information. These less common kinds of bladder cancer (apart from sarcoma) are treated similarly to TCCs, especially in the early stages, but alternative drugs may be used if chemotherapy is required.
Major organizations are investing on the research to utilize nano-technology as a means to deliver drugs into the human body. nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale.
This method of delivery helps doctors to offer a simple and effective way of treating bladder cancer in their patients, due to the fact that the nanoparticles used in the treatment can attack the cancerous cells directly without harming the surrounding cells.
Bladder Cancer Drugs Market size & Market analysis
Source : https://www.researchandmarkets.com/reports/5559826/bladder-cancer-drugs-global-market-report-2022